| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Cash Flows From Operating Activities: | ||||||
Net loss | ||||||
-8,325 | -3,336 | -833 | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
46 | 21 | - | ||||
Depreciation and amortization | ||||||
- | - | 6 | ||||
Warranty provision | ||||||
13 | 0 | - | ||||
Inventory write-off | ||||||
-193 | 0 | - | ||||
Non-cash lease expense | ||||||
80 | 0 | - | ||||
Stock-based compensation expense | ||||||
1,536 | 512 | 0 | ||||
Common shares issued for services | ||||||
102 | 0 | - | ||||
Changes in assets and liabilities: | ||||||
Accounts receivable | ||||||
190 | 4 | - | ||||
Inventories | ||||||
1,892 | 27 | 131 | ||||
Prepaid expenses and other current assets | ||||||
136 | 63 | -16 | ||||
Accounts payable | ||||||
174 | 196 | 24 | ||||
Operating lease liability | ||||||
-62 | 0 | - | ||||
Customer deposits | ||||||
343 | 0 | - | ||||
Accrued liabilities and other | ||||||
112 | 8 | 57 | ||||
Deferred compensation | ||||||
-96 | 0 | 26 | ||||
Deferred revenue | ||||||
2 | 0 | - | ||||
Net cash used in operating activities | ||||||
-8,485 | -2,692 | -833 | ||||
Cash Flows From Investing Activities: | ||||||
Capital expenditures for property and equipment | ||||||
256 | 14 | 35 | ||||
Investment in patents and trademarks | ||||||
114 | 120 | - | ||||
Investment in patents and trademarks | ||||||
- | - | 0 | ||||
Long-term deposits | ||||||
11 | 0 | - | ||||
Net cash used in investing activities | ||||||
-382 | -134 | -35 | ||||
Cash Flows From Financing Activities: | ||||||
Sale of common stock and warrants | ||||||
12,499 | 13,683 | 3,767 | ||||
Offering costs paid on sale of stock and warrants | ||||||
1,148 | 1,542 | - | ||||
Proceeds from exercise of warrants | ||||||
2,112 | 0 | - | ||||
Offering costs paid on exercise of warrants | ||||||
28 | 0 | - | ||||
Proceeds from exercise of stock options | ||||||
58 | 0 | - | ||||
Offering costs paid | ||||||
- | - | 70 | ||||
Payment of notes payable | ||||||
0 | 39 | 0 | ||||
Net cash provided by financing activities | ||||||
13,492 | 12,101 | 3,697 | ||||
Net decrease in cash and cash equivalents | ||||||
4,624 | 9,274 | 2,828 | ||||
Supplemental Disclosure of Non-Cash Investing and Financing Activities: | ||||||
Interest paid | ||||||
0 | 1 | 0 | ||||
Prepaid insurance financed with note payable | ||||||
0 | 39 | 0 | ||||
Right-of-use assets and liabilites recorded during period | ||||||
341 | 0 | - | ||||
Issuance costs relating to warrants issued to public offering selling agent | ||||||
205 | 664 | - | ||||
Issuance costs relating to warrants issued to private offering selling agent | ||||||
- | - | 0 | ||||